Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x.
The last decade in oncology has been highlighted by the emergence of novel, highly specific anti-cancer agents, targeting a variety of molecular structures and able to inhibit aberrantly activated oncogenic pathways. Epidermal growth factor receptor inhibitors (EGFRIs) represent one type of such "targeted" agents. Their use made treatment more tolerable and resulted in significant reduction of systemic adverse effects. However, EGFRIs are associated with toxicities affecting the skin and adnexal structures, and mucosal surfaces that affect the majority of treated patients. Significant dermatologic toxicities have changed the role and involvement of dermatologists in their care. It is essential to be familiar with these adverse effects, potential complications, long-term sequelae, and available effective treatment strategies in order to appropriately manage these patients. This review will describe the clinical presentation, histopathology, underlying mechanisms, and management options, emphasizing evidence-based approaches.
在过去的十年中，肿瘤学领域出现了新型的高度特异性抗癌药物，这些药物针对多种分子结构，并能够抑制异常激活的致癌途径。表皮生长因子受体抑制剂 (EGFRIs) 就是这类“靶向”药物的一种。它们的使用使治疗更耐受，并显著减少了全身不良反应。然而，EGFRIs 与影响皮肤和附属结构以及影响大多数治疗患者的粘膜表面的毒性有关。显著的皮肤毒性改变了皮肤科医生在治疗中的作用和参与。熟悉这些不良反应、潜在并发症、长期后果以及可用的有效治疗策略对于妥善管理这些患者至关重要。这篇综述将描述临床表型、组织病理学、潜在机制和管理选择，强调循证方法。
